Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Fingolimod

A package comprising:

• a) a first pharmaceutical composition comprising an amount of laquinimod and a pharmaceutically acceptable carrier;
• b) a second pharmaceutical composition comprising an amount of fingolimod and a pharmaceutically acceptable carrier;
• and
• c) instructions for use of the first and second pharmaceutical compositions together to treat a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

A therapeutic package for dispensing to, or for use in dispensing to, a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome, which comprises:

• a) one or more unit doses, each such unit dose comprising:
• an amount of laquinimod and
• ii) an amount of fingolimod
• wherein the respective amounts of said laquinimod and said fingolimod in said unit dose are effective, upon concomitant administration to said subject, to treat the subject, and
• b) a finished pharmaceutical container therefor, said container containing said unit dose or unit doses, said container further containing or comprising labeling directing the use of said package in the treatment of said subject.